NCT03770260View on ClinicalTrials.gov

Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to Treatment

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

February 10, 2020

Primary Completion Date

September 12, 2022

Study Completion Date

July 6, 2023

Conditions
Recurrent Multiple MyelomaRefractory Multiple Myeloma
Interventions
DRUG

Ixazomib Citrate

Given PO

DRUG

Pevonedistat

Given IV

Trial Locations (9)

27710

Duke University Medical Center, Durham

30322

Emory University Hospital/Winship Cancer Institute, Atlanta

33607

Moffitt Cancer Center-International Plaza, Tampa

33612

Moffitt Cancer Center - McKinley Campus, Tampa

Moffitt Cancer Center, Tampa

40536

University of Kentucky/Markey Cancer Center, Lexington

43210

Ohio State University Comprehensive Cancer Center, Columbus

06510

Smilow Cancer Center/Yale-New Haven Hospital, New Haven

06520

Yale University, New Haven

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT03770260 - Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to Treatment | Biotech Hunter | Biotech Hunter